Delayed Diagnosis of Graves’ Ophthalmopathy: Case Report

Öz

Thyroid diseases are common endocrine disorders worldwide. They may occur due to either increased hormonal activity or decreased hormone production. Thyrotoxicosis refers to the presence of elevated thyroid hormone levels in the blood, whereas hyperthyroidism refers to increased synthesis and secretion of thyroid hormones. Graves' disease is the most common cause of hyperthyroidism. Thyroid ophthalmopathy is the most common extrathyroidal manifestation of Graves' disease. Graves' ophthalmopathy is an autoimmune condition affecting the orbital and extraocular muscles, the pathogenesis of which is not fully understood. Management of Graves' ophthalmopathy should begin with achieving and maintaining euthyroidism. Accurate diagnosis of thyroid diseases relies on a careful medical history, physical examination, and laboratory evaluation. This article discusses the role of primary care and preventive approaches in a patient with delayed diagnosis of Graves' ophthalmopathy.

Anahtar Kelimeler

• Hyperthyroidism
• Ophthalmopathy
• TSH Receptor Antibodies (TRab)

Tanıda Geç Kalınmış Graves Oftalmopatisi: Olgu Sunumu

Öz

Tiroid hastalıkları ülkemizde ve tüm dünyada yaygın olarak görülen endokrin hastalıklardandır. Tiroid hastalıkları ya artmış hormonal aktivite ya da hormon üretim azlığına bağlı olarak seyretmektedir. Çeşitli nedenlerle kanda tiroid hormonunun artmasına tirotoksikoz,; tiroid bezinin normalden çok çalışarak aşırı miktarda tiroid hormonu üretmesine ise hipertiroidi denir. Graves hastalığı ise hipertiroidinin en sık görülen nedenidir. Graves hastalığının en sık görülen tiroid dışı tutulumu tiroid oftalmopatisidir. Graves oftalmopatisi; patogenezi tam anlaşılmayan, orbita ve ekstraoküler kasları etkileyen otoimmün bir hastalıktır. Graves oftalmopati yönetimi eşlik eden tiroid hastalığının kontrolü ile başlamalıdır. Tiroid hastalıklarında doğru tanı dikkatli bir öykü, fizik muayene ve laboratuvar araştırması ile elde edilir. Yazımızda birinci basamak sağlık hizmetlerine başvuran, tanıda geç kalınmış graves oftalmopatisi olan hastanın problemlerine yaklaşım ele alınmıştır.

Anahtar Kelimeler

• Hipertiroidizm
• Oftalmopati
• TSH Reseptör Antikoru (TRAb)

Kaynakça

1. 1. Hoang TD, Stocker DJ, Chou EL, Burch HB. 2022 Update on Clinical Management of Graves’ Disease and Thyroid Eye Disease. Endocrinol Metab Clin North Am. 2022; 51(2): 287–304.
2. 2. Lane LC, Wood CL, Cheetham T. Graves' disease: moving forwards. Arch Dis Child. 2023;108 (4):276-81.
3. 3. Lee SY, Pearce EN. Hyperthyroidism: A Review. JAMA. 2023;330(15):1472–83.
4. 4. Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velázquez-Villoria A, Galofré JC. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J Ophthalmol. 2015;249125.
5. 5. Panagiotou G, Perros P. Asymmetric Graves’ orbitopathy. Front Endocrinol (Lausanne). 2020;11:611845.
6. 6. Bartalena L, Marcocci C, Pinchera A. Graves’ ophthalmopathy: a preventable disease? Eur J Endocrinol. 2002; 146: 457-61.
7. 7. Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM et al. Management of Thyroid Eye Disease: A Consensus Statement by the American Thyroid Association and the European Thyroid Association. Thyroid. 2022;32(12):1439-70.
8. 8. Republic of Turkey Ministry of Health, Public Health Institution of Turkey. Periodic health examination and screening tests recommended in family medicine practice. Publication No: 991. Ankara: Republic of Turkey Ministry of Health; 2015.

9. 9. Schübel J, Stahl A, Feldkamp J, Werner F, Uebel T, Voigt, K. Thyroid Nodules: Diagnosis and Treatment in Primary Care. Dtsch Arztebl Int. 2025;112(13):341-7.
10. 10. Kahaly GJ, Diana T, Olivo PD. TSH receptor antibodies: relevance & utility. Endocr Pract. 2020;26(1):97– 106.
11. 11. Ippolito S, Cusini C, Lasalvia P, Gianfagna F, Veronesi G, Gallo D, et al. Change in newly diagnosed Graves’ disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression. J Endocrinol Invest. 2021; 44:1707–18.
12. 12. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, et al. Prevalence and natural history of Graves’ orbitopathy in a large series of newly diagnosed Graves’ hyperthyroidism seen at a single center. J Clin Endocrinol Metab. 2013; 98:1443–9.
13. 13. Wagner RS. Diagnosing and Treating Thyroid Ophthalmopathy. J Pediatr Ophthalmol Strabismus. 2018;55(6):355.
14. 14. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, et al. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol. 2021; 185:43–67.
15. 15. Şahlı E, Gündüz K. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol 2017;47: 94-105.